Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia
Open Access
- 29 December 2015
- journal article
- research article
- Published by Hindawi Limited in Gastroenterology Research and Practice
- Vol. 2016, 1-6
Abstract
Aim. To evaluate the compliance and virological response to pegylated interferon alpha 2a treatment of chronic hepatitis B in Roma population compared to majority Caucasian population in Slovakia.Methods. Retrospective evaluation of a cohort of all Roma patients treated with pegylated interferon alpha 2a from 2007 to 2013 in 3 centers for treatment of chronic viral hepatitis B. The Study included 43 Roma patients with chronic viral hepatitis B and randomly selected control group. Treatment duration was 48 weeks. Viral response was evaluated after 24 weeks, at the end of treatment, and 24 weeks after the end of treatment.Results. Complete treatment course was finished by 79.1% of Roma patients compared to all patients from the control group. There was a tendency toward lower viral response rate in Roma at all time points; however significant difference was only at end of treatment viral response (51.2% Roma versus 81.4% majority,). We also did not find significant difference at the rate of HBsAg loss.Conclusion. Roma patients with chronic hepatitis B have significantly worse compliance to treatment with pegylated interferon and they have significantly lower rate of end of treatment viral response.
Keywords
Funding Information
- University in Košice
This publication has 24 references indexed in Scilit:
- Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in JapanJournal of Gastroenterology, 2012
- Prevalence of HBV genotypes in Central and Eastern EuropeJournal of Medical Virology, 2008
- Chronic hepatitis BHepatology, 2007
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2005
- Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype DGut, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Natural History and Prognosis of Hepatitis BSeminars in Liver Disease, 2003
- Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian IndiansJournal of Gastroenterology and Hepatology, 1998
- Efficacy of low-dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: a randomized controlled trialJournal of Hepatology, 1996
- Global programme for control of hepatitis B infectionVaccine, 1995